Resverlogix (RVX.TO) Stock Price
Resverlogix Price
Revenue at Resverlogix has contracted by 15.3% per year over the past 3 years to 140,000.00 USD. Earnings per share have declined at 15.8% per year over the last 10 years. Resverlogix's net margin stands at -13,500.0%, down from -2,613.0% several years earlier.
Resverlogix stock price
Details
Stock Price
ⓘHow to Read This Chart
This chart tracks the historical stock price of Resverlogix over time. You can switch between daily, weekly, and monthly views and select custom time ranges — from a single day to the full available history. Use the toggle to view price changes in absolute currency terms or as a percentage change relative to the starting date.
Total Return vs. Price Return
The "Total Return" toggle includes reinvested dividends on top of the pure price movement. This is critical because dividends can account for a significant portion of long-term returns. Historically, roughly 40 % of the S&P 500's total return has come from dividends. Always compare total return when evaluating a stock's real performance against a benchmark.
Intraday Price Data
When viewing a one-day time frame, the chart displays real-time intraday price movements. This is useful for observing how Resverlogix stock reacts to market openings, earnings releases, or breaking news throughout the trading session.
What to Look For
Look for long-term trends (sustained upward or downward movements over months and years), support and resistance levels (price zones where the stock repeatedly bounces or reverses), and volatility (how much the price fluctuates day to day). Comparing Resverlogix's price chart to a market index like the S&P 500 can reveal whether the stock is outperforming or underperforming the broader market.
| Date | Resverlogix Price |
|---|---|
| 9/10/2026 | 0.07 USD |
| 9/9/2026 | 0.07 USD |
| 9/8/2026 | 0.07 USD |
| 9/4/2026 | 0.07 USD |
| 9/3/2026 | 0.07 USD |
| 9/2/2026 | 0.07 USD |
| 9/1/2026 | 0.07 USD |
| 8/31/2026 | 0.07 USD |
| 8/28/2026 | 0.07 USD |
| 8/27/2026 | 0.07 USD |
| 8/26/2026 | 0.07 USD |
| 8/25/2026 | 0.08 USD |
| 8/24/2026 | 0.07 USD |
| 8/21/2026 | 0.07 USD |
| 8/20/2026 | 0.07 USD |
| 8/19/2026 | 0.07 USD |
| 8/18/2026 | 0.07 USD |
| 8/17/2026 | 0.07 USD |
| 8/14/2026 | 0.08 USD |
| 8/13/2026 | 0.08 USD |
| 8/12/2026 | 0.07 USD |
| 8/11/2026 | 0.07 USD |
| 8/10/2026 | 0.07 USD |
| 8/7/2026 | 0.07 USD |
| 8/6/2026 | 0.07 USD |
| 8/5/2026 | 0.07 USD |
| 8/4/2026 | 0.08 USD |
| 7/31/2026 | 0.07 USD |
| 7/30/2026 | 0.07 USD |
| 7/29/2026 | 0.07 USD |
Resverlogix Revenue, EBIT, Net Income
3 Years
5 Years
10 Years
25 Years
Max
Details
Resverlogix Income Statement, Balance Sheet, Cash Flow Statement
| REVENUEM USD |
|---|
| REVENUE GROWTH% |
| EBITM USD |
| EBIT MARGIN% |
| NET INCOMEM USD |
| NET INCOME GROWTH% |
| SHARESM |
| 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025e | 2029e | 2030e |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| – | – | – | – | – | – | – | – | – | – | – | – | – | 7.00 | 13.00 | 13.00 |
| – | – | – | – | – | – | – | – | – | – | – | – | – | – | 85.71 | – |
| -34.00 | -13.00 | -8.00 | -20.00 | -34.00 | -41.00 | -38.00 | -21.00 | -9.00 | -15.00 | -11.00 | -5.00 | -4.00 | – | – | – |
| – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – |
| -43.00 | 55.00 | -18.00 | -19.00 | -46.00 | -58.00 | -162.00 | 118.00 | 1.00 | -24.00 | -3.00 | -16.00 | -7.00 | -36.00 | -82.00 | – |
| 138.89 | -227.91 | -132.73 | 5.56 | 142.11 | 26.09 | 179.31 | -172.84 | -99.15 | -2,500.00 | -87.50 | 433.33 | -56.25 | 414.29 | 127.78 | – |
| 74.22 | 80.43 | 85.08 | 100.98 | 105.35 | 177.19 | 188.10 | 221.43 | 231.85 | 239.87 | 254.42 | 269.96 | 276.60 | 276.60 | 276.60 | 276.60 |
Details
Income Statement Key Figures
ⓘRevenue and Revenue Growth
Revenue is the starting point of every income statement — it measures the total sales Resverlogix generates from its core business. Revenue growth (expressed as year-over-year percentage change) is one of the most important indicators of business momentum. Sustained growth above 10 % annually is generally considered strong, while declining revenue is a serious warning sign that demands investigation.
Gross Margin
Gross margin = (Revenue − Cost of Goods Sold) ÷ Revenue. It reveals what percentage of each dollar of revenue Resverlogix retains after direct production costs. High gross margins (above 50 %) are typical of asset-light businesses like software and brands, while capital-intensive industries like manufacturing often operate below 30 %. Compare Resverlogix's gross margin to industry peers and track it over time to spot improving or deteriorating pricing power.
EBIT and EBIT Margin
EBIT measures operating profit — what remains after subtracting all operating expenses (including R&D, sales, and administrative costs) from gross profit. The EBIT margin shows this as a percentage of revenue. Because it excludes interest and taxes, EBIT allows fair comparisons between companies with different debt levels and tax jurisdictions. A rising EBIT margin indicates improving operational efficiency.
Net Income and Earnings Per Share (EPS)
Net income is the company's final profit after all expenses, interest, and taxes. Dividing net income by the number of shares outstanding gives you EPS — the single most influential metric in stock valuation. Consistent EPS growth is the primary driver of long-term stock price appreciation. Always check whether EPS growth comes from genuine profit improvement or from share buybacks reducing the share count.
Shares Outstanding
The total number of shares Resverlogix has issued. A declining share count (through buybacks) boosts EPS and signals management confidence. A rising share count (through stock issuance) dilutes existing shareholders. Always monitor this number alongside EPS to get the full picture of per-share value creation.
Analyst Estimates
The projected figures represent consensus estimates from professional analysts. Compare these forecasts against Resverlogix's historical growth rates to assess whether expectations are realistic. A company that consistently beats consensus estimates tends to see its stock price rewarded over time, while repeated misses erode investor confidence.
Resverlogix stock margins
3 Years
5 Years
10 Years
25 Years
Max
Details
Resverlogix Stock Revenue, EBIT, Earnings per Share
3 Years
5 Years
10 Years
25 Years
Max
Details
Resverlogix business model & stock analysis
Resverlogix SWOT Analysis
Strengths
Resverlogix Corp benefits from a robust scientific foundation, backed by years of research and development in the field of epigenetics. This provides the company with a strong base for innovative drug discovery and development, enabling them to potentially address unmet medical needs.
Resverlogix Corp has a promising drug pipeline with multiple compounds in different stages of development. This diversification reduces their dependency on a single product and increases the potential for revenue generation in the future. It also allows the company to target various therapeutic areas, expanding their market opportunity.
Weaknesses
Resverlogix Corp heavily relies on the success of its clinical trials to demonstrate the safety and efficacy of its drug candidates. Delays or failures in clinical trials can significantly impact the company's progress and financial performance. The unpredictable nature of clinical trials poses a potential weakness for the company.
Resverlogix Corp may face challenges due to limited financial resources for conducting extensive research and development activities. This can impact their ability to accelerate the development of their drug candidates or explore new opportunities. Seeking additional funding through partnerships or investments may be necessary to overcome this weakness.
Opportunities
Resverlogix Corp has the opportunity to expand its market presence by targeting emerging markets and therapeutic areas with unmet medical needs. By identifying and addressing these untapped markets, the company can diversify its revenue streams and potentially achieve substantial growth.
Resverlogix Corp can explore strategic partnerships and collaborations with pharmaceutical companies, research institutions, or academic organizations. Such partnerships can provide access to additional resources, expertise, and market leverage, accelerating the development and commercialization of their drug candidates.
Threats
Resverlogix Corp operates in a highly regulated industry where regulatory approval is imperative for market entry. Delays, rejections, or stringent regulations from health authorities can pose significant threats to the company's ability to bring their drug candidates to market and generate revenues.
Resverlogix Corp faces intense competition from other pharmaceutical companies, both established players and emerging biotech firms. The presence of strong competitors with similar drug candidates or innovative solutions can limit market share and create challenges for product differentiation and commercial success.
Resverlogix Eulerpool Fair Value
Details
Fair Value Estimate
ⓘWhat Is Fair Value?
Fair value is an estimate of what a stock is truly "worth" based on its financial fundamentals, independent of the current market price. If the calculated fair value is above the current share price, the stock may be undervalued — and vice versa. This chart shows three different fair value approaches so you can cross-check them against each other.
Earnings-Based Fair Value
Calculated by multiplying the current earnings per share (EPS) by the average historical P/E ratio over a selected multi-year period. The smoothing over several years filters out temporary spikes or dips. If this fair value exceeds the market price, it suggests the stock is cheap relative to its earning power.
Example: Fair Value (Earnings) 2022 = EPS 2022 × Average P/E 2019–2021
Revenue-Based Fair Value
Derived by multiplying revenue per share by the average historical price-to-sales ratio. This method is particularly useful for companies with volatile or temporarily depressed earnings, as revenue tends to be more stable than profits. It answers: "At what price has the market historically valued each dollar of this company's sales?"
Example: Fair Value (Revenue) 2022 = Revenue per Share 2022 × Average P/S 2019–2021
Dividend-Based Fair Value
Calculated by dividing the dividend per share by the average historical dividend yield. This approach is most relevant for mature, consistently dividend-paying companies. If the resulting fair value is higher than the current price, it implies the stock offers a better yield than its historical average.
Example: Fair Value (Dividend) 2022 = Dividend per Share 2022 ÷ Average Yield 2019–2021
How to Use This Chart
When all three fair value lines converge above the current price, it strengthens the case that the stock is undervalued. When they diverge, investigate why — it may indicate a structural shift in margins, payout policy, or growth rate. The forward estimates on the right extend the analysis using projected fundamentals, helping you assess whether the current price already reflects future growth expectations.
Resverlogix historical P/E ratio, EBIT multiple, and P/S ratio
Resverlogix annual returns
Details
Annual Return
ⓘWhat This Chart Shows
This chart breaks down 's total annual return into two components: price return (gains or losses from stock price movement) and dividend return (income received from dividend payments). Together, they represent the total return an investor would have earned in each calendar year.
Price Return
Price return measures the percentage change in 's stock price from January 1st to December 31st of each year. Positive bars indicate the stock appreciated; negative bars show a decline. This is the component most investors focus on, but it tells only part of the story — especially for dividend-paying stocks.
Dividend Return
Dividend return represents the income generated from dividends paid during the year, expressed as a percentage of the starting stock price. While it may seem small in any single year (typically 1–4 % for established companies), dividends compound significantly over decades and have historically contributed roughly 40 % of total stock market returns.
What to Look For
Examine how many years showed positive vs. negative returns to gauge consistency. A stock with mostly positive years and small drawdowns suggests lower risk. Also compare 's annual returns to a benchmark index — consistently outperforming the market is a hallmark of a strong investment. Pay attention to the worst years: understanding downside risk is just as important as chasing upside potential.
Resverlogix shares outstanding
3 Years
5 Years
10 Years
25 Years
Max
Details
Resverlogix shareholder structure
| % | Name |
|---|---|
30.83343% | |
1.90282% | |
0.64475% | |
0.03871% | |
0.03796% |
Resverlogix Executives and Management Board
7 members · avg. age 56 · 14 % women
Mr. Donald Mccaffrey
Chairman of the Board, President, Chief Executive Officer, Secretary · since 2003
565,200.00 USD
Management
Dr. Michael Sweeney
Senior Vice President - Clinical Development
Mr. A. Brad Cann
Chief Financial Officer
Dr. Ewelina Kulikowski
Chief Scientific Officer
Board of Directors
Mr. Kelly Mcneill
Lead Independent Director · since 2006
Mr. Siu Lun To (56)
Independent Director
Mr. Kenneth Zuerblis
Independent Director
Frequently asked questions about Resverlogix
The business model of Resverlogix Corp is focused on developing innovative therapies in the field of epigenetics to address unmet medical needs. The company specializes in the discovery and development of small molecules that target specific proteins involved in the regulation of gene expression. Resverlogix Corp aims to provide novel treatments for conditions such as cardiovascular diseases and other related disorders. By leveraging their expertise in epigenetics, the company strives to offer groundbreaking therapies that have the potential to significantly improve patients' lives.
Resverlogix Corp is primarily active in the pharmaceutical industry.
Some of the main competitors of Resverlogix Corp in the market include Novartis AG, Pfizer Inc., Amgen Inc., and AstraZeneca PLC.
Resverlogix Corp, founded in 2001, is a Canadian biotechnology company specializing in developing innovative therapies for cardiovascular diseases. The company focuses on addressing unmet medical needs, primarily targeting high-risk patients with chronic diseases. Resverlogix Corp is at the forefront of pioneering epigenetic drug discovery and development, specifically targeting BET bromodomain inhibition. Their leading compound, Apabetalone, has shown promising results in clinical trials, demonstrating its potential to reduce major adverse cardiovascular events. With a commitment to improving patient outcomes and advancing cardiovascular health, Resverlogix Corp has emerged as a prominent player in the biotech industry.
Resverlogix Corp has achieved several significant milestones in its journey. The company successfully completed Phase 3 clinical trials for its lead drug candidate, apabetalone, for the treatment of high-risk cardiovascular diseases. Moreover, Resverlogix Corp received a Special Protocol Assessment from the U.S. FDA for the Phase 3 BETonMACE trial, indicating the agency's support for the trial design. The company's achievements also include securing strategic partnerships and collaborations with renowned pharmaceutical companies, enhancing its research capabilities and market presence. These milestones demonstrate Resverlogix Corp's commitment to advancing innovative treatments for serious diseases and highlights its strong potential for growth and success in the pharmaceutical industry.
Resverlogix Corp is primarily present in Canada and the United States.
Resverlogix Corp represents values of innovation, excellence, and commitment to improving patients' lives. With a strong corporate philosophy focused on advancing groundbreaking medical treatments, Resverlogix Corp strives to redefine the standard of care in cardiovascular diseases. Through their leading-edge drug development platform, BETonMACE™, the company aims to deliver transformative therapies that target unmet medical needs. Resverlogix Corp is dedicated to scientific excellence, collaboration with global experts, and ensuring the highest ethical standards in their research and development endeavors. Through their unwavering dedication, Resverlogix Corp is committed to making a positive impact on the lives of patients worldwide.
5 analysts currently rate the Resverlogix stock: 4 recommend buying, 1 holding and 0 selling.
Converted at the current exchange rate, the Resverlogix share trades at 0.06 EUR (0.07 USD).
The Resverlogix share (RVX.TO) is listed on 6 stock exchanges, including: Frankfurt (RFS.F), München (RFS.MU), Düsseldorf (RFS.DU), London (0VF9.L), Toronto (RVX.TO).
Resverlogix Corp is a biopharmaceutical company focused on developing drugs that target lipid and lipoprotein metabolism. The company was founded in 2001 and is headquartered in Calgary, Canada. Resverlogix Corp specializes in the discovery and development of therapeutics for the treatment of serious diseases such as Alzheimer's, Parkinson's, cancer, and diabetes.
The revenue cannot currently be calculated for Resverlogix.
The profit cannot currently be calculated for Resverlogix.
The P/E ratio cannot be calculated for Resverlogix at the moment.
The P/S cannot be calculated for Resverlogix currently.
The Eulerpool Quality Score for Resverlogix is 2/10.
The ISIN of Resverlogix is CA76128M1086. The ISIN (International Securities Identification Number) is a globally unique identifier for securities.
The WKN of Resverlogix is A0DP7L. The WKN (Wertpapierkennnummer) is a six-digit German security identification number.
The ticker of Resverlogix is RVX.TO. The ticker symbol is used to trade Resverlogix shares on the stock exchange.
Resverlogix paid dividends every year for the past 0 years.
Resverlogix is assigned to the 'Health' sector.
The dividends of Resverlogix are distributed in USD.
Resverlogix stock
Resverlogix Peer Group
Resverlogix Ticker
Resverlogix FIGI
All fundamentals and in-depth analysis of Resverlogix
Our stock analysis for Resverlogix stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Resverlogix. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.